Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 14;20(1):61.
doi: 10.5334/gh.1443. eCollection 2025.

Calcium Channel Blockers: Key Medicine to Drive Global Hypertension Control

Andrew E Moran  1   2 , Swagata Kumar Sahoo  1 , Bolanle Banigbe  1 , Sohel Reza Choudhury  3 , Prabhdeep Kaur  4 , Renu Garg  1
Affiliations
Editorial

Calcium Channel Blockers: Key Medicine to Drive Global Hypertension Control

Andrew E Moran et al. Glob Heart. .
No abstract available

Keywords: antihypertensive medicine; calcium channel blocker; global health; hypertension; low- and middle-income country; medicine access; patient-centered care; team-based care.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

References

    1. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Available from: https://www.who.int/publications/i/item/9789240081062.
    1. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967. DOI: 10.1016/S0140-6736(15)01225-8 - DOI - PubMed
    1. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, Investigators AT. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28. DOI: 10.1056/NEJMoa0806182 - DOI - PubMed
    1. Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, Grobbee DE, Narkiewicz K, Ojji DB, Poulter NR, Schlaich MP, Oparil S, Spiering W, Williams B, Wright JT Jr., Lakshman P, Uluwattage W, Hay P, Pereira T, Amarasena N, Ranasinghe G, Gianacas C, Shanthakumar M, Liu X, Wang N, Gnanenthiran SR, Whelton PK, Investigators GM. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404:1536–1546. DOI: 10.1016/S0140-6736(24)01744-6 - DOI - PubMed
    1. Abrar A, Hu X, Akhtar J, Jubayer S, Noor Nabi Sayem M, Sultana S, Al Mamun MA, Bhuiyan MR, Malik F, Amin MR, Alim A, Gupta R, Zhao D, Farrell M, Banigbe B, Matsushita K, Burka D, Appel L, Moran AE, Choudhury SR. Evaluation of the World Health Organization-HEARTS hypertension control package in Bangladesh: a quasi-experimental trial. Heart. 2024;110:1090–1098. DOI: 10.1136/heartjnl-2024-324253 - DOI - PMC - PubMed

Publication types